intuitive surgical investor presentation 2021intuitive surgical investor presentation 2021

Investor's Business Daily . All Rights Reserved. During 2021, COVID-19 resurgences continued to impact da Vinci procedure volumes. These forward-looking statements should, therefore, be considered in light of various important factors, including, but not limited to, the following: the risk that the COVID-19 pandemic could lead to further material delays and cancellations of, or reduced demand for, procedures; curtailed or delayed capital spending by hospitals; disruption to our supply chain, including increased difficulties in obtaining a sufficient amount of materials in the semiconductor and other markets; closures of our facilities; delays in surgeon training; delays in gathering clinical evidence; delays in obtaining new product approvals or clearances from the U.S. Food and Drug Administration (FDA) due to the effects of the COVID-19 pandemic; the evaluation of the risks of robotic-assisted surgery in the presence of infectious diseases; diversion of management and other resources to respond to the COVID-19 outbreaks; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 pandemic continues to disrupt local economies and causes economies in our key markets to enter prolonged recessions; the risk of our inability to comply with complex FDA and other regulations, which may result in significant enforcement actions; healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and market acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including our joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; our completion of and ability to successfully integrate acquisitions, including Orpheus Medical; procedures counts; regulatory approvals, clearances, and restrictions or any dispute that may occur with any regulatory body; guidelines and recommendations in the healthcare and patient communities; intellectual property positions and litigation; competition in the medical device industry and in the specific markets in which we operate; risks associated with our operations outside of the U.S.; unanticipated manufacturing disruptions or the inability to meet demand for products; our reliance on sole and single source suppliers; the results of legal proceedings to which we are or may become a party; product liability and other litigation claims; adverse publicity regarding us and the safety of our products and adequacy of training; our ability to expand into foreign markets; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements; and other risk factors. your options for e-mail notification, please enter your e-mail address below and click The Companys calculated non-GAAP effective tax rate is generally higher than its GAAP effective tax rate. Submit. Where are we going with this one? Please go ahead. And then now we have rolled it out to most other markets in the first six months of this year, except for China where there are longer regulatory timelines. From a market perspective, about 60%-ish or so are sleeves, about 15% are revisions. A couple of things I'd say. As the phases of the pandemic evolve, we're supporting our team in addressing the opportunities and challenges posed by the pandemic and the ways we work. Good afternoon, and welcome to Intuitive's second-quarter earnings conference call. The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance by excluding items such as intangible asset charges, share-based compensation (SBC) and long-term incentive plan expenses, and other special items. The authors concluded, "The results revealed that robotic-assisted thoracic surgery is a feasible and safe technique compared with VATs in terms of short-term and long-term outcomes." Investors are cautioned not to place undue reliance on such forward-looking statements. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. In terms of our underlying numbers, we're growing at a little faster rate in the revision section, sleeves and bypass grow about the same rate. That says that we're not putting out more capital than folks need, even though it's been healthy capital quarters, it means our customers are getting good benefit out of what they're using those systems for. INTUITIVE SURGICAL, INC.UNAUDITED QUARTERLY CONDENSED CONSOLIDATED STATEMENTS OF INCOME (IN MILLIONS, EXCEPT PER SHARE DATA), INTUITIVE SURGICAL, INC.UNAUDITED TWELVE MONTHS ENDED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (IN MILLIONS, EXCEPT PER SHARE DATA), INTUITIVE SURGICAL, INC.UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (IN MILLIONS), INTUITIVE SURGICAL, INC.UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES(IN MILLIONS, EXCEPT PER SHARE DATA), Contact: Investor Relations(408) 523-2161. SUNNYVALE, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Intuitive (the Company) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended December31, 2021. Compound annual growth between the second quarters of 2019 and 2021 was 16.5%. Yeah. We will now open the call to your questions. So it's hard to time it out, and it doesn't time out over one or two quarters, it times out over years. Customer appreciation and recurring use of our products has been growing nicely. Ladies and gentlemen, thank you for standing by and welcome to the Intuitive Q4 2021 Earnings Release Call. . The system features an ultra-thin, ultra-maneuverable catheter that allows navigation far into the peripheral lung and provides the unprecedented stability necessary for precision in biopsy. You've been spending a lot there. The supply issues we called out in the first quarter did not impact Ion placements and procedures in this quarter. [Operator instructions] As a reminder, this conference is being recorded. Macroeconomic conditions created by COVID could regionally impact hospital capital spending. That's right -- theythink these 10stocks are even better buys. We did not repurchase any shares in the quarter. And U.S. general surgery, in particular, performed well. Capital placements for the first six months of 2021 were in line with procedure and utilization growth. The Company uses these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. Roughly a third of our team works in the manufacturer test and distribution of our products. Intuitive Surgical Investor Presentation. Frankly, the lack of precision in that estimate is such that it's probably not useful for us to share. The increase in cash in the second quarter primarily reflected cash from operations and stock exercises. The Company presents constant currency revenue to provide a framework for assessing how our underlying business performed excluding the effect of foreign currency fluctuations. ET. [Operator Instructions] As a reminder, today's call is being recorded. Intuitive Surgical Investor Relations. We also believe that growth benefited from some procedures that were previously deferred due to delays in testing and patient concern over COVID. We're doing that as a combination of My Intuitive plus some of the simulation work that we do, plus some of the machine learning and video analysis work that we do. Thank you for joining us today. That means that utilization will go up kind of naturally, that that mix moves toward a higher utilization mix. I think that's what's been driving our success in the early market. Clinical trial sites completed enrollment for our PRECIsE clinical trial. Listen to Webcast. Again, if you look across that two-year period, try to look through the pandemic kind of ups and downs, what we're seeing is that procedure demand is there. Outside the U.S., we placed 115 systems in the second quarter, compared with 72 in the second quarter of 2020 and 108 systems last quarter. In addition, the components of the costs that the Company excludes in its calculation of non-GAAP net income attributable to Intuitive Surgical, Inc. and non-GAAP EPS may differ from the components that its peer companies exclude when they report their results of operations. 2021 Intuitive Surgical Inc - - USD 2020 Intuitive Surgical Inc . 2021 Proxy Statement - Special Meeting 224.6 KB. Product and research reports and data presentation to medical specialists, sales force, new channels, investors. We believe value creation in surgery and acute care is foundationally human. This MMR report includes investor recommendations based on a thorough examination of the Thoracic Surgery Market's contemporary competitive scenario. We also expect spending to increase as a percentage of revenue as investments in headcount, infrastructure, and other support areas catch up to the growth in the business. How close we are to maybe seeing something that you can monetize? OUS markets grew 51% year over year or 19% on a two-year compound annual growth rate basis. The Motley Fool recommends the following options: long January 2022 $580 calls on Intuitive Surgical and short January 2022 $600 calls on Intuitive Surgical. Copyright 2023 Intuitive Surgical. To change your e-mail options at The next page will display a menu of options. Some of them are fully included because we feel like they make us more efficient and to make them more efficient. The outlook we are providing on today's call does not reflect risks associated with a significant increase in COVID-related hospitalizations in relation to the Delta variant or other potential new variants. (1) Services revenue includes the effect of the following item: (2) Selling, general and administrative includes the effect of the following item: (3) Income from operations includes the effect of the following item: (4) Interest and other income, net includes the effect of the following item: (5) Income tax expense includes the effect of the following items: Excess tax benefits related to share-based compensation arrangements. And I suspect that's most of what we're seeing, at least in the United States in terms of that. Accordingly, they are subject to significant volatility based on the performance of these metrics and are not tied to performance of the Companys business within the period. We've seen a few teams come out and field systems that are alternatives to ours. We're doing what we call the procedure development and the trial development around other indications, we think there'll be an opportunity in thoracic, as well as other ones beyond it. any time, re-enter your e-mail address and click Submit, then adjust your form entries. Intuitive Surgical, Inc. (Nasdaq:ISRG), headquartered in Sunnyvale, Calif., is the pioneer and a global technology leader in robotic-assisted, minimally invasive surgery. Last quarter, we forecast 2021 procedure growth of 22% to 26%. We continue to operate in a challenging supply chain environment and have experienced longer lead times and delayed deliveries from our suppliers. Our second-quarter pro forma net income was $477 million or $3.92 per share, compared with $132 million or $1.11 per share for the second quarter of 2020 and $427 million or $3.52 per share for the last quarter. Listen to Webcast. The Company excludes the excess tax benefits or deficiencies associated with SBC arrangements as well as the tax effects associated with non-cash amortization of deferred tax assets related to intra-entity non-inventory transfers, because the Company does not believe these items correlate with the on-going results of its core operations. I think we're going to have to let it play for another few quarters to see. And I think for a subset of the benign procedures that have been kind of deferred elective procedures, hospitals can recover those pretty quickly. I think the thing that we'd call out is it's not the case rates per se to monitor. Mehr Brsen-Nachrichten . We expect pro forma other income, which is comprised mostly of interest income, to total between $50 million and $55 million in 2021. While the percentage of systems placed under operating leases fluctuates quarter to quarter, we believe leasing will increase as a percentage of sales over time, which will result in the deferral of otherwise current revenue into future periods. We continue to see significant utilization variance by region due to pandemic differences. Affiliated with the world's largest international neurotechnology community, NeurotechX, with 18,000+ members . your options for e-mail notification, please enter your e-mail address below and click Trade-in activity can fluctuate and be difficult to predict. Second-quarter system average selling prices decreased to $1.55 million from $1.65 million for both the second quarter of 2020 and the first quarter of 2021. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The compound annual growth rate between the fourth quarter of 2019 and the fourth quarter of 2021 was 10%. The compound annual growth rate between the second quarter of 2019 and the second quarter of 2021 was 16.5%. Marshall, the operating margin coming in at the 43%, I'm just wondering how much we can extrapolate here? 2022 Proxy Statement 36.4 MB. And we've received feedback -- positive feedback from surgeons who have indicated that system access has been a key driver for increased procedures. INTUITIVE at 43rd Annual Goldman Sachs Global Healthcare Conference. We expect our pro forma rate for the last six months of 2021 to be between 21% and 22% versus our previous guidance of 20% to 21%, reflecting a greater proportion of U.S. income for the year. Moving on to capital placements. And we're building into the broader digital ecosystem for SP. Our pro forma spending grew over 24% from a year ago, representing increased investment in our business. Fourth quarter 2021 instruments and accessories revenue increased by 13% to $843million, compared with $747million in the fourth quarter of 2020, primarily driven by approximately 19% growth in da Vinci procedure volume, partially offset by stocking orders in the prior year associated with the Companys launch of Extended Use Instruments. From a U.S. perspective, I think it's early, and I think we're simply acknowledging the risk. So I think all of you on the call, you should expect increased alternatives for the customer base. Forward-looking statements relate to expectations concerning matters that are not historical facts. We expect these programs to continue their ramp as our labs and development programs recover efficiency. The adjustments between pro forma and GAAP net income are outlined and quantified on our website. My Intuitive allows surgeons and care team members to access their data, to manage their profile, their learning, and otherwise interact with Intuitive through an easy-to-use mobile app in the palm of their hand. Both gynecology and urology procedure annualized growth strengthened in the quarter, as pandemic pressures eased in the U.S. Fourth quarter 2022 GAAP net income attributable to Intuitive Surgical, Inc. included excess tax benefits of $18 million, or $0.05 per diluted share, compared with $27 million, or $0.07 per diluted share, in the fourth quarter of 2021. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. The fourth quarter 2022 system placements included 154systems placed under operating lease and usage-based arrangements, compared with 143 systems in thefourth quarter of 2021. Our teams continue to work closely with hospitals, physicians, and care teams in pursuit of what our customers have termed the Quadruple Aim: Better, more predictable patient outcomes, better experiences for patients, better experiences for their care teams, and ultimately, a lower total cost to treat. You have to do it. And that has implications for the kind of imaging we do, it has implications for task analysis and training, and we're doing those things, and those can be aggregated across a surgical platform. My name is Kari Krogstad.

Surefire 660 Led Upgrade, Newzjunky Watertown Ny Breaking News, Articles I